TUTadashi Umehara

Tadashi Umehara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tadashi Umehara has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Hidetomo Murakami

    Department of Neurology, The Jikei University School of Medicine

    18 shared publications
  • Hiromasa Matsuno

    Department of Neurology, The Jikei University School of Medicine

    18 shared publications
  • Shusaku Omoto

    Department of Neurology, Katsushika Medical Center, The Jikei University School of Medicine, Tokyo, Japan

    14 shared publications
  • Yasuyuki Iguchi

    Department of Neurology, The Jikei University School of Medicine, 3-19-18, Tokyo, 105-8471, Japan

    14 shared publications
  • Tomotaka Shiraishi

    Department of Neurology, The Jikei University School of Medicine, 3-19-18, Tokyo, 105-8471, Japan

    13 shared publications
  • Hisayoshi Oka

    Department of Neurology, Daisan Hospital, The Jikei University School of Medicine, 4-11-1, Izumihoncho, Komae-shi, Tokyo, 201-8601, Japan

    10 shared publications

Latest Publications

  • Cardiac Sympathetic Dysfunction Reveals Asymmetric Dopaminergic Neurodegeneration in Drug-naive Parkinson Disease

    by Tadashi Umehara, Yoshitaka Nakayama, Hiromasa Matsuno, Shusaku Omoto, Renpei Sengoku, Hidetomo Murakami, Yasuyuki Iguchi

    Purpose: Asymmetric nigrostriatal dopaminergic degeneration in Parkinson disease (PD) is linked to motor and nonmotor manifestations and may reflect Lewy body propagation patterns, particularly in brain-first pathology. The clinical determinants of nigrostriatal dopaminergic asymmetry, however, remain unclear. Methods: We studied 121 drug-naive patients with PD to examine associations between the striatal asymmetry index (AI) and clinical features, including olfactory function, constipation, and cardiac sympathetic dysfunction measured by 123 I-metaiodobenzylguanidine (MIBG) scintigraphy. Results: Patients with pronounced striatal asymmetry (AI >20%) exhibited lower prevalences of hypertension and smoking, a higher frequency of tremor-dominant phenotype, and predominantly right-sided motor symptoms compared with those with symmetric dopaminergic degeneration (AI ≤20%). They also had higher cardiac 123 I-MIBG uptake and less severe orthostatic blood pressure decline. Unexpectedly, olfactory dysfunction severity was not associated with striatal AI. Multivariable regression analysis revealed that cardiac sympathetic dysfunction independently and robustly correlates with symmetric degeneration of nigrostriatal dopaminergic neurons (β=0.287, t =3.032, P =0.003). Hierarchical clustering grouped cardiac sympathetic dysfunction and striatal AI in the same lowest-level cluster (linkage dissimilarity = 0.66), indicating a close association. Patients exhibiting markedly reduced cardiac 123 I-MIBG uptake demonstrated more symmetric dopaminergic degeneration compared with those with normal uptake (striatal AI: 10.8±10.2% vs. 23.5±15.8%; P =0.003). Conclusions: Cardiac sympathetic Lewy body burden appears to play a central role in shaping nigrostriatal dopaminergic asymmetry in early PD. Cardiac sympathetic denervation may act as a phenotypic modifier, influencing the spatial pattern of neurodegeneration and contributing to clinical heterogeneity.

  • HDL cholesterol indicates neurodegenerative vulnerability in dementia with lewy bodies

    by Tadashi Umehara, Masahiro Mimori, Masakazu Ozawa, Tomotaka Shiraishi, Tomomichi Kitagawa, Hiromasa Matsuno, Shusaku Omoto, Renpei Sengoku, Hidetomo Murakami, Yasuyuki Iguchi

    Altered lipid metabolism has been implicated in neurodegenerative disorders; however, its relevance to dementia with Lewy bodies (DLB) remains incompletely characterized. This study examined associations between plasma lipid profiles, lipid-related inflammatory indices, and clinical and neurodegenerative features in drug-naive patients with DLB, with comparisons to age-matched healthy controls. Plasma levels of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol did not differ significantly between patients with DLB and controls, whereas triglyceride (TG) levels were significantly lower in DLB (p = 0.002). Within the DLB cohort, higher HDL-C levels were associated with less severe neurodegenerative changes, including milder nigrostriatal degeneration (β = 0.448, p = 0.005), lower motor symptom severity (β = -0.324, p = 0.047), and a reduced prevalence of visual hallucinations (OR = 0.924, p = 0.006). In contrast, higher TG levels and an increased TG-to-HDL-C ratio were associated with more pronounced neurodegenerative involvement (TG: β = -0.358, p = 0.021; TG-to-HDL-C ratio: β = -0.426, p = 0.006). Greater neurodegenerative severity was also associated with lipid-related inflammatory markers, including the neutrophil-to-HDL-C ratio (β = -0.491, p = 0.001) and the platelet-to-HDL-C ratio (β = -0.301, p = 0.040), suggesting that inflammation may act as a contributory or mediating process. Collectively, these findings indicate that plasma lipid profiles-particularly HDL-C-are associated with neurodegeneration and clinical manifestations in DLB, extending beyond isolated dopaminergic involvement. An HDL-C-related neurodegenerative framework, with inflammation as a modifying process, may better reflect the underlying pathophysiology of DLB and warrants further longitudinal investigation.


  • Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease

    by Masahiro Mimori, Tadashi Umehara, Hiroki Takatsu, Motohiro Okumura, Marina Masui, Hiroyuki Kida, Masakazu Ozawa, Haruhiko Motegi, Asako Onda, Hiromasa Matsuno, et al.

    The relationship between plasma or cerebrospinal fluid (CSF) amino acid levels and the pathophysiology of Parkinson's disease (PD) remains unclear. We aimed to examine the association of plasma and CSF amino acid levels with the nigrostriatal dopaminergic neurons and the clinical symptoms of newly diagnosed drug-naïve patients with PD. This was a cross-sectional study using the Jikei University PD registry. A total of 45 amino acids were measured in both plasma and CSF, and their associations with key clinical parameters were investigated. Multiple linear regression analyses were conducted to evaluate whether amino acids served as major explanatory variables for clinical parameters in PD. Forty-five drug-naïve patients were enrolled. The mean age was 68.6 ± 9.6, and disease duration was 2.5 years (± 2.1). MDS-UPDRS Part III score averaged 28.1 (± 13.3). Among the measured plasma and CSF amino acids, only CSF taurine levels were identified as independent factors for SBR, MDS-UPDRS Part II, and Part III scores in multivariate analysis (β = 0.39 [95% CI 0.13 to 0.65, p = 0.005], -0.46 [95% CI -0.76 to -0.15, p = 0.004], -0.39 [95% CI -0.73 to -0.05, p = 0.02], respectively). Higher CSF taurine levels were associated with more preserved SBR on 123I-FP-CIT SPECT and better activities of daily living and motor symptoms, suggesting that CSF taurine may be involved in the mechanism of nigrostriatal dopaminergic degeneration and exert a neuroprotective effect on dopaminergic neurons.

  • Association of blood pressure variability with white matter hyperintensities and nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease

    by Hiromasa Matsuno, Tadashi Umehara, Masahiro Mimori, Masakazu Ozawa, Tomotaka Shiraishi, Asako Onda, Keiko Bono, Shusaku Omoto, Renpei Sengoku, Hidetomo Murakami, et al.

    Blood pressure variability, white matter brain lesions and degeneration of nigrostriatal dopaminergic neurons may be associated with each other in patients with Parkinson’s disease (PD). We examined the coefficient of variation of systolic blood pressure (CV-sBP) in 122 drug-naïve patients with newly diagnosed PD. The association of CV-sBP with degree of white matter hyperintensities and striatal specific binding ratio (SBR) of 123I-2 carbomethoxy-3-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) were examined taking cardiovascular risk factors into account. The results showed that patients with higher CV-sBP were older (r = 0.362, p < 0.001) and had severer periventricular hyperintensities (PVH) (r = 0.261, p = 0.002), deep and subcortical white matter hyperintensities (DSWMH) (r = 0.237, p = 0.004) and lower striatal SBR (right SBR: r = − 0.269, p = 0.002, left SBR: r = − 0.341, p < 0.001). Patients with severer PVH or DSWMH had lower striatal SBR (PVH: r = − 0.317, p < 0.001, DSWMH: r = − 0.350, p < 0.001). CV-sBP was significantly associated with left striatal SBR (β =–0.264, p = 0.008), especially left caudate SBR (β = − 0.181, p = 0.044) after controlling for age, sex, motor severity, hypertension, diabetes, and DSWMH grade. In conclusion, higher blood pressure variability was associated with greater dopaminergic degeneration in the left striatum, independently of white matter hyperintensity grade. Whether this association reflects dopaminergic neuronal loss or structural alterations in the striatum remains unclear.


  • Enhanced visual illusions in Parkinson’s disease with cardiovascular autonomic failure

    by Tadashi Umehara, Masahiro Mimori, Tatsushi Kokubu, Masakazu Ozawa, Tomotaka Shiraishi, Asako Onda, Hiromasa Matsuno, Shusaku Omoto, Hidetomo Murakami, Yasuyuki Iguchi

    Purpose Few studies have examined the association between cardiovascular autonomic failure and minor hallucinations in patients with Parkinson’s disease (PD). The aim of this study was to clarify this association. Methods The subjects were 133 patients with PD without well-structured visual hallucinations. Visual illusory responses were evaluated using the noise pareidolia test. Cardiac 123I-metaiodobenzylguanidine (123I-MIBG) uptake and neurogenic orthostatic hypotension (nOH) and supine hypertension (nSH) on head-up tilt-table testing were examined in association with the incidence of pareidolia. Results Fifty-one (38%) patients had pareidolia. nOH (β = 0.220, p = 0.008), cognitive impairment (β = −0.228, p = 0.028), and longer symptom duration (β = 0.273, p = 0.006) were associated with an increased incidence of pareidolia independently of age, sex, motor severity, levodopa-equivalent dose, and anticholinergic and cholinesterase inhibitor use. An increased incidence of pareidolia was also associated with nSH (β = 0.214, p = 0.009), while no such association was found with cardiac 123I-MIBG uptake. Patients with severe nOH or nSH tended to have a higher incidence of pareidolia than those with mild nOH (p = 0.063) or nSH (p < 0.003), respectively. Conclusion nOH and nSH were associated with the severity of pareidolia in early PD patients without well-structured visual hallucinations. Further studies are required to clarify whether this association is attributable to widespread central pathological changes related to cardiovascular autonomic failure, or to degeneration of the sympathetic nervous system.


  • Sleep disturbance is associated with worsening quality of life in patients with multiple system atrophy

    by Masakazu Ozawa, Hidetomo Murakami, Tomotaka Shiraishi, Hiromasa Matsuno, Keiko Bono, Tadashi Umehara, Shusaku Omoto, Renpei Sengoku, Hideyuki Shimizu, Hiroki Sarukawa, et al.


  • Open Access

    Enhanced visual illusions in Parkinson’s disease with neurogenic orthostatic hypotension

    by Tadashi Umehara, Masahiro Mimori, Tatsushi Kokubu, Masakazu Ozawa, Tomotaka Shiraishi, Asako Onda, Hiromasa Matsuno, Shusaku Omoto, Hidetomo Murakami, Yasuyuki Iguchi

    Purpose: Accumulating evidence suggests that sympathetic noradrenergic system degeneration is associated with the pathophysiology of minor hallucination in patients with Parkinson’s disease (PD). We aimed to elucidate the relationship between visual illusion and the extent and type of cardiovascular sympathetic failure in patients with PD. Methods: The subjects were 133 patients with PD without well-structured visual hallucinations. Visual illusory responses were evaluated using the noise pareidolia test. Cardiac 123I-metaiodobenzylguanidine uptake and neurogenic orthostatic hypotension (nOH) and supine hypertension (nSH) on head-up tilt-table testing were examined in association with the number of illusory responses. Results: Fifty-one (38%) patients had illusory responses. nOH (β = 0.220, p = 0.008), cognitive impairment (β = −0.228, p = 0.028), and longer symptom duration (β = 0.273, p = 0.006) were associated with greater numbers of illusory responses independently of age, sex, motor severity, levodopa equivalent dose, and anticholinergic and cholinesterase inhibitor use; nSH and peripheral sympathetic degeneration reflected by low cardiac 123I-metaiodobenzylguanidine uptake were not. Although nSH and peripheral sympathetic degeneration had no effects on the association between the number of illusory responses and nOH, patients with severe nOH had significantly more illusory responses than those with mild nOH (p = 0.048). Conclusion: nOH was associated with the severity of visual illusion in early PD patients without well-structured visual hallucinations, whereas nSH and peripheral sympathetic degeneration were not. These findings deepen our knowledge of the role of sympathetic noradrenergic degeneration in minor hallucinations and may have prognostic implications in patients with early PD.

  • Association between sebum secretion and cardiac sympathetic dysfunction in Parkinson's disease

    by Tomomichi Kitagawa, Renpei Sengoku, Masakazu Ozawa, Hiromasa Matsuno, Tadashi Umehara, Atsuo Nakahara, Hisayoshi Oka


  • Serum phosphorus levels associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson's disease

    by Tadashi Umehara, Masahiro Mimori, Tatsushi Kokubu, Masakazu Ozawa, Tomotaka Shiraishi, Takeo Sato, Asako Onda, Hiromasa Matsuno, Shusaku Omoto, Hidetomo Murakami, et al.


  • Peripheral immune profile in drug-naïve dementia with Lewy bodies

    by Tadashi Umehara, Masahiro Mimori, Tatsushi Kokubu, Masakazu Ozawa, Tomotaka Shiraishi, Takeo Sato, Asako Onda, Hiromasa Matsuno, Shusaku Omoto, Renpei Sengoku, et al.

    Background Accumulating evidence suggests that peripheral inflammation is associated with the pathogenesis of Parkinson’s disease (PD). We examined peripheral immune profiles and their association with clinical characteristics in patients with DLB and compared these with values in patients with PD. Methods We analyzed peripheral blood from 93 participants (drug-naïve DLB, 31; drug-naïve PD, 31; controls, 31). Absolute leukocyte counts, absolute counts of leukocyte subpopulations, and peripheral blood inflammatory indices such as neutrophil-to-lymphocyte ratio were examined. Associations with clinical characteristics, cardiac sympathetic denervation, and striatal 123I-2-carbomethoxy-3-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) binding were also examined. Results Patients with DLB had lower absolute lymphocyte and basophil counts than did age-matched controls (both; p < 0.005). Higher basophil counts were marginally associated with higher global cognition (p = 0.054) and were significantly associated with milder motor severity (p = 0.020) and higher striatal 123I-FP-CIT binding (p = 0.038). By contrast, higher basophil counts were associated with more advanced PD characterized by decreased global cognition and severe cardiac sympathetic denervation. Although lower lymphocyte counts had relevance to more advanced PD, they had little relevance to clinical characteristics in patients with DLB. Higher peripheral blood inflammatory indices were associated with lower body mass index in both DLB and PD. Conclusions As in patients with PD, the peripheral immune profile is altered in patients with DLB. Some peripheral immune cell counts and inflammatory indices reflect the degree of disease progression. These findings may deepen our knowledge on the role of peripheral inflammation in the pathogenesis of DLB.